

Special Issue

African Swine Fever Virus Vaccine Development

Message from the Guest Editors

African Swine Fever Virus is a large, enveloped double-stranded DNA virus. ASFV is a highly infectious and severe hemorrhagic disease that affects pigs, causing a wide range of clinical signs. Issues such as homologous recombination, delayed onset, and the potential for secondary infections pose significant risks, and the performance of the gene-deleted live vaccine still requires further study. While inactivated vaccines, subunit vaccines, and vector-based ASF vaccines are generally considered safer, their efficacy is not enough to protect against higher doses of virulent viruses in inoculated infections.

We must investigate the changes that occur during viral infection and the resulting pathogenesis while also focusing on vaccine research to provide a solid foundation for preventing and controlling ASF.

We welcome original research articles and reviews on topics including (but not limited to) the followings:

- **Virus infection and dissemination**
- **Pathogenicity, migratory patterns, tissue tropism, and distribution in pigs**
- **Research on immune responses and the protective effects of various types of ASF vaccines**

Guest Editors

Dr. Faming Miao

Dr. Hong Jia

Dr. Lian-Feng Li

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/232858

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).